GlassScriptPhysician profile
Payal Patel
NPI 1912140781
$1,107.26
in general payments reported to CMS, 2019-2025
14 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.51 · 2021: $154 · 2022: $221 · 2023: $142 · 2024: $300 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $181.07 | 2024-2025 | Xdemvy |
| Polynovo North America LLC | $155.51 | 2024 | Novosorb Btm |
| Horizon Therapeutics Plc | $150.28 | 2022-2023 | Tepezza |
| Amgen INC. | $129.90 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $102.15 | 2022-2023 | Hydrus Microstent |
| Aerie Pharmaceuticals, INC. | $96.83 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $57.17 | 2021 | |
| Oyster Point Pharma, INC. | $55.87 | 2023-2025 | Tyrvaya, Ryzumvi |
| Insulet Corporation | $40.08 | 2023 | Omnipod |
| Eyevance Pharmaceuticals LLC | $32.66 | 2023 | Zerviate, Flarex |
| Bausch & Lomb Americas INC. | $31.36 | 2023-2024 | Miebo, Vyzulta |
| Stryker Corporation | $30.51 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.89 | 2025 | |
| Abbvie INC. | $16.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.